Two anti-CD38 monoclonal antibodies, isatuximab (humanized immunoglobulin [Ig]G1,κ) and daratumumab (human IgG1,κ), are currently approved for MM patients [5, 12–16]. The gene discussed is CD38; the disease is Miyoshi myopathy.